Abstract:The Human immunodeficiency virus (HIV) is the causative agent of acquired immunodeficiency syndrome (AIDS), one of the most perilous diseases known to humankind. A 2023 estimate put the number of people living with HIV around 40 million worldwide, with the majority benefiting from various antiretroviral therapies. Consequently, the urgent need for the development of effective drugs to combat this virus cannot be overstated. In the realm of medicinal and organic chemistry, the synthesis and identification of novel compounds capable of inhibiting HIV enzymes at different stages of their life cycle are of paramount importance. Notably, the spotlight is on the progress made in enhancing the potency of HIV inhibitors through the use of piperazine-based compounds. Multiple studies have revealed that the incorporation of a piperazine moiety results in a noteworthy enhancement of anti-HIV activity. The piperazine ring assumes a pivotal role in shaping the pharmacophore responsible for inhibiting HIV-1 at critical stage, including attachment, reverse transcription, integration, and protease activity. This review also sheds light on the various opportunities that can be exploited to develop effective antiretroviral targets and eliminate latent HIV reservoirs. The advancement of highly potent analogues in HIV inhibitor research has been greatly facilitated by contemporary medicinal strategies, including molecular/fragment hybridization, structure-based drug design, and bioisosterism. These techniques have opened up new avenues for the development of compounds with enhanced efficacy in combating the virus.

Design, Synthesis, and Biological Activity of Novel 1,4-Disubstituted Piperidine/piperazine Derivatives As CCR5 Antagonist-Based HIV-1 Entry Inhibitors

Design, Synthesis, and Biological Evaluation of Novel 2-Methylpiperazine Derivatives As Potent CCR5 Antagonists.

Design, Synthesis and Biological Evaluation of Novel Piperazine Derivatives As CCR5 Antagonists

Design, Synthesis, and Biological Evaluation of Novel Piperidine-4-carboxamide Derivatives As Potent CCR5 Inhibitors

Design, Synthesis and Biological Activity of Bicyclic Piperidine-Based HIV-1 Inhibitors

Synthesis and biological evaluation of novel piperidin-4-ol derivatives

Discovery and Mechanistic Investigation of Piperazinone Phenylalanine Derivatives with Terminal Indole or Benzene Ring as Novel HIV-1 Capsid Modulators

Design, synthesis, and antiviral evaluation of novel piperidine-substituted arylpyrimidines as HIV-1 NNRTIs by exploring the hydrophobic channel of NNIBP

Discovery of Piperidine‐Linked Pyridine Analogues As Potent Non‐nucleoside HIV‐1 Reverse Transcriptase Inhibitors

Indazolyl-substituted Piperidin-4-yl-aminopyrimidines As HIV-1 NNRTIs: Design, Synthesis and Biological Activities.

Design, Synthesis and Anti-Hiv-1 RT Evaluation of 2-(Benzyl(4-chlorophenyl)amino)-1-(piperazin-1-yl)ethanone Derivatives.

Synthesis and Anti-HIV-1 Activity Evaluation for Novel 3a,6a-Dihydro-1H-pyrrolo[3,4-c]pyrazole-4,6-dione Derivatives.

Discovery of Piperidin-4-yl-aminopyrimidine Derivatives As Potent Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors.

Discovery of diarylpyrimidine derivatives bearing piperazine sulfonyl as potent HIV-1 nonnucleoside reverse transcriptase inhibitors

Optimization of the Antiviral Potency and Lipophilicity of Halogenated 2,6‐diarylpyridinamines As a Novel Class of HIV‐1 NNRTIS

Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs

Medicinal Chemistry Perspectives on the Development of Piperazine-Containing HIV-1 Inhibitors

Design of Biphenyl-Substituted Diarylpyrimidines with a Cyanomethyl Linker as HIV-1 NNRTIs via a Molecular Hybridization Strategy.

Design,synthesis and activity evaluation of new anti-HIV-1 CXCR4 inhibitors

Synthesis and Biological Evaluation of Novel N-[3-(4-phenylpip-erazin-1-yl)-propyl]-carboxamide Derivatives

Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives As a Novel Series of CC-Chemokine Receptor 5 Antagonists.